Association Between Metformin Therapy and Mortality After Breast Cancer

Lega, Iliana C.; Austin, Peter C.; Gruneir, Andrea; Goodwin, Pamela J.; Rochon, Paula A.; Lipscombe, Lorraine L.

doi:10.2337/dc12-2535

Cited by 97 publications

(115 citation statements)

References 31 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…High heterogeneity was identified in these studies (I 2 =75%), but no publication bias. He et al (63) demonstrated that administration of metformin markedly decreased mortality specific to breast cancer (63), although their findings did not correlate with the results of two other studies (67,68). The RR in these studies was 0.83 (95% CI, 0.63-1.08; P= 0.16), and moderate heterogeneity was apparent (I 2 =47%) (57).…”

Section: Clinical Studies Of Metformin In Gynecological Cancermentioning

confidence: 72%

“…In these studies, the RR of treatment with metformin was 0.49 (95% CI, 0.32-0.73; P= 0.001), with no difference in the results in meta-analysis and no heterogeneity (I 2 = 0%) (58). A total of four studies have demonstrated that metformin improves overall mortality in breast cancer (63)(64)(65)(66), contrarily to three other studies (67)(68)(69), which did not observe any efficacy for this drug. The RR of treatment with metformin in the aforementioned studies was 0.70 (95% CI, 0.55-0.88; P=0.003) (58).…”

Section: Clinical Studies Of Metformin In Gynecological Cancermentioning

confidence: 99%

See 1 more Smart Citation

Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning

et al. 2016

View full text Add to dashboard Cite

Abstract. Metformin is a first-line drug used for the treatment of type 2 diabetes. Recently, metformin has been reported to reduce the carcinogenic risk and inhibit tumor cell growth in glioma and breast cancer. The anticancer action of metformin involves the enhancement of phosphorylation of liver kinase B1, activation of adenosine monophosphate-activated protein kinase and inhibition of mammalian target of rapamycin, which reduces cell growth. Metformin is anticipated to exert antitumor effects in gynecological cancer, and its efficacy for the treatment of endometrial, breast and ovarian cancer has been suggested in preclinical studies and clinical trials. Although the effect of metformin on cervical cancer remains to be examined in clinical trials, its antitumor effects have been reported in preclinical studies. Thus, the use of metformin for the treatment of gynecological cancer may become a successful example of drug repositioning, following establishment of the drug's antitumor effects, risk evaluation, screening and validation of efficacy.

show abstract

Section: Clinical Studies Of Metformin In Gynecological Cancermentioning

confidence: 72%

Section: Clinical Studies Of Metformin In Gynecological Cancermentioning

confidence: 99%

Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In previous work, we showed that metformin use after a breast cancer diagnosis is not associated with decreased all-cause mortality 13 . Although metformin use was associated with lower breast cancer-specific mortality, our results did not reach statistical significance.…”

Section: Discussionmentioning

confidence: 99%

“…Metformin, an insulin-sensitizing medication used to treat diabetes, has been associated with reduced tumour growth [4][5][6][7] and improved pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy 8 . Furthermore, observational studies have shown a lower risk of breast 9,10 and other cancers 11,12 and lower breast cancer mortality 13 in women with diabetes treated with metformin.…”

Section: Introductionmentioning

confidence: 99%

Metformin and Breast Cancer Stage at Diagnosis: A Population-Based Study

et al. 2017

View full text Add to dashboard Cite

PurposeThe objective of the present study was to use a large, population-based cohort to examine the association between metformin and breast cancer stage at diagnosis while accounting for mammography differences. MethodsWe used data from Ontario administrative health databases to identify women 68 years of age or older with diabetes and invasive breast cancer diagnosed from 1 January 2007 to 31 December 2012. Adjusted logistic regression models were used to compare breast cancer stage at diagnosis (stages i and ii vs. iii and iv) between the women exposed and not exposed to metformin. We also examined the association between metformin use and estrogen receptor status, tumour size, and lymph node status in the subset of women for whom those data were available. ResultsWe identified 3125 women with diabetes and breast cancer; 1519 (48.6%) had been exposed to metformin before their cancer diagnosis. Median age at breast cancer diagnosis was 76 years (interquartile range: 72-82 years), and mean duration of diabetes was 8.8 ± 5.9 years. In multivariable analyses, metformin exposure was not associated with an earlier stage of breast cancer (odds ratio: 0.98; 95% confidence interval: 0.81 to 1.19). In secondary analyses, metformin exposure was not associated with estrogen receptor-positive breast cancer, tumours larger than 2 cm, or positive lymph nodes. ConclusionsThis population-based study did not show an association between metformin use and breast cancer stage or tumour characteristics at diagnosis. Our study considered older women with long-standing diabetes, and therefore further studies in younger patients could be warranted.

show abstract

“…В нескольких исследованиях не было отмечено преиму-ществ в ОВ и БРВ при использовании МТФ после ради-кального лечения больных РМЖ [40][41][42][43]. Однако есть дан-ные и о положительном влиянии препарата на показатели ОВ и БРВ.…”

Section: Introductionunclassified